# Immunotherapy

## Immunotherapy

## Immunotherapy

## Immunotherapy

* Tumor Mutational Burden and Response Rate to PD-1 Inhibition

N Engl J Med 2017; 377:2500-2501[December 21, 2017](http://www.nejm.org/toc/nejm/377/25/)DOI: 10.1056/NEJMc1713444

<http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC>

* Tumor Mutational Burden and Response Rate to PD-1 Inhibition

N Engl J Med 2017; 377:2500-2501[December 21, 2017](http://www.nejm.org/toc/nejm/377/25/)DOI: 10.1056/NEJMc1713444

<http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC>

* Tumor Mutational Burden and Response Rate to PD-1 Inhibition

N Engl J Med 2017; 377:2500-2501[December 21, 2017](http://www.nejm.org/toc/nejm/377/25/)DOI: 10.1056/NEJMc1713444

<http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC>

* Tumor Mutational Burden and Response Rate to PD-1 Inhibition

N Engl J Med 2017; 377:2500-2501[December 21, 2017](http://www.nejm.org/toc/nejm/377/25/)DOI: 10.1056/NEJMc1713444

<http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC>

## Immunotherapy

* Tumor Mutational Burden and Response Rate to PD-1 Inhibition

N Engl J Med 2017; 377:2500-2501[December 21, 2017](http://www.nejm.org/toc/nejm/377/25/)DOI: 10.1056/NEJMc1713444

<http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC>

{% embed url="<https://twitter.com/RitterLab/status/1514742717162541056>" %}